Validation of the Edmonton‐33: A Patient‐Reported Outcome Instrument in Head and Neck Oncology at Baseline and Subacute Phases Post‐Treatment
Journal of Oral Pathology & Medicine · 2025
DOI: 10.1111/jop.13640 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Oral Pathology & Medicine, 2025. Verfasst von K Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Schulich School of Medicine & Dentistry, Western University, London, Canada. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Mouth Neoplasms. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Patient‐reported outcomes (PRO), which prioritize patient perspectives, are highly valuable for patient‐centered care in Head and Neck Oncology. The objective of this study was to explore the longitudinal validity of the Edmonton‐33 (E‐33), a PRO instrument for assessing head and neck functions in swallowing, chewing, dry mouth, and speech.
Methods
This study involved 59 adult patients (18 female, 41 male) with squamous cell carcinoma (SCC) of the oral cavity. Participants provided consent and completed the E‐33 and other PRO instruments before and after surgical and radiation treatment at months 3 ( n = 18), 6 ( n = 18), and 9 ( n = 16). Data were collected (from June 2021 to August 2024) and analyzed for correlation between domains of the E‐33 and their domain‐specific, previously validated counterparts before treatment (baseline) and after treatment (Months 3, 6, and 9).
Results
There were statistically significant correlations ( p < 0.05) between all E‐33 domains and their domain‐specific counterparts at baseline and at post‐treatment month 6. At Months 3 and 9 post‐treatment, there were partial correlations between E‐33 domains and some domain‐specific counterparts.
Conclusion
The E‐33 demonstrates validity pre‐treatment and post‐treatment at subacute timepoint (Months 6) for capturing data on swallowing, chewing, dry mouth, and speech, similar to other previously validated instruments. This validity is limited at the more acute timepoint of 3 months post‐treatment and the later timepoint of 9 months post‐treatment. Additional data are needed to further explore the long‐term validity at further longitudinal timepoints at 1 and 2 years post‐treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Schulich School of Medicine & Dentistry, Western University, London, Canada.
- London Health Sciences Centre, London, Canada.
- Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, Canada.
Zitieren
APA
Zhang, K., Khan, H., Seikaly, H., Nichols, A., Fung, K., MacNeil, S. D., & Mendez, A. (2025). Validation of the Edmonton‐33: A Patient‐Reported Outcome Instrument in Head and Neck Oncology at Baseline and Subacute Phases Post‐Treatment. Journal of Oral Pathology & Medicine. https://doi.org/10.1111/jop.13640
Vancouver
Zhang K, Khan H, Seikaly H, Nichols A, Fung K, MacNeil SD, et al. Validation of the Edmonton‐33: A Patient‐Reported Outcome Instrument in Head and Neck Oncology at Baseline and Subacute Phases Post‐Treatment. Journal of Oral Pathology & Medicine. 2025. doi:10.1111/jop.13640
BibTeX
@article{Zhang2025,
author = {Zhang, K and Khan, H and Seikaly, H and Nichols, A and Fung, K and MacNeil, S D and Mendez, A},
title = {Validation of the Edmonton‐33: A Patient‐Reported Outcome Instrument in Head and Neck Oncology at Baseline and Subacute Phases Post‐Treatment},
journal = {Journal of Oral Pathology & Medicine},
year = {2025},
doi = {10.1111/jop.13640}
}
EUVIMED